AKT3 and neoplasm: PDXCs from MAS98.12PR and MAS98.12 generally preserved the main molecular differences detected in the PDXs i.e. up-regulation of SFKs, MAPK/ERK pT202/204 and AKT3 in the resistant tumor tissue (Supplementary Fig. 6B).